PY1996328A - Compuestos de azalactam como inhibidores de hpk1 - Google Patents

Compuestos de azalactam como inhibidores de hpk1

Info

Publication number
PY1996328A
PY1996328A PY201901996328A PY1996328A PY1996328A PY 1996328 A PY1996328 A PY 1996328A PY 201901996328 A PY201901996328 A PY 201901996328A PY 1996328 A PY1996328 A PY 1996328A PY 1996328 A PY1996328 A PY 1996328A
Authority
PY
Paraguay
Prior art keywords
sup
compounds
azalactam
pharmaceutically acceptable
acceptable salts
Prior art date
Application number
PY201901996328A
Other languages
English (en)
Inventor
Omar Khaled Ahmad
Dechert Schmitt Anne-Marie
Bel Matthew Del
Rebecca Anne Gallego
Mingying He
Mehran Jalaie
Ted William Johnson
Robert Steven Kania
Michele Mctigue
Sajiv Krishnan Nair
Jamison Bryce Tuttle
Dahui Zhou
Ru Zhou
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=68771726&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PY1996328(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of PY1996328A publication Critical patent/PY1996328A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invención se refiere a compuestos de la Fórmula general (I) y sales de estos aceptables desde el punto de vista farmacéutico, en donde R<sup>1</sup>, R<sup>1a</sup>, R<sup>2</sup>, , R<sup>3</sup>, R<sup>4</sup>, y (R<sup>5</sup>)<sub>a</sub> son como se definen en la presente, a composiciones farmacéuticas que comprenden dichos compuestos y sales de estos aceptables desde el punto de vista farmacéutico, y a métodos de uso de dichos compuestos, sales de estos aceptables desde el punto de vista farmacéutico y composiciones para el tratamiento del crecimiento anormal de células, que incluye cáncer.
PY201901996328A 2018-11-15 2019-11-15 Compuestos de azalactam como inhibidores de hpk1 PY1996328A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862767602P 2018-11-15 2018-11-15
US201962909970P 2019-10-03 2019-10-03

Publications (1)

Publication Number Publication Date
PY1996328A true PY1996328A (es) 2021-05-21

Family

ID=68771726

Family Applications (1)

Application Number Title Priority Date Filing Date
PY201901996328A PY1996328A (es) 2018-11-15 2019-11-15 Compuestos de azalactam como inhibidores de hpk1

Country Status (38)

Country Link
US (1) US11142525B2 (es)
EP (1) EP3880676B1 (es)
JP (1) JP7118267B2 (es)
KR (1) KR20210090675A (es)
CN (1) CN113316576A (es)
AU (1) AU2019378184B2 (es)
BR (1) BR112021008991A2 (es)
CA (1) CA3061392A1 (es)
CL (1) CL2021001190A1 (es)
CO (1) CO2021006114A2 (es)
CR (1) CR20210251A (es)
CU (1) CU20210035A7 (es)
CY (1) CY1126663T1 (es)
DK (1) DK3880676T3 (es)
DO (1) DOP2021000088A (es)
EC (1) ECSP21034668A (es)
ES (1) ES2958948T3 (es)
FI (1) FI3880676T3 (es)
GE (2) GEAP202215630A (es)
HR (1) HRP20231089T1 (es)
HU (1) HUE063367T2 (es)
IL (1) IL283149A (es)
LT (1) LT3880676T (es)
MD (1) MD3880676T2 (es)
MX (1) MX2021005754A (es)
PE (1) PE20211868A1 (es)
PH (1) PH12021551117A1 (es)
PL (1) PL3880676T3 (es)
PT (1) PT3880676T (es)
PY (1) PY1996328A (es)
RS (1) RS64655B1 (es)
SG (1) SG11202104394XA (es)
SI (1) SI3880676T1 (es)
TW (1) TWI718758B (es)
UA (1) UA127426C2 (es)
UY (1) UY38471A (es)
WO (1) WO2020100027A1 (es)
ZA (1) ZA202103099B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020092528A1 (en) 2018-10-31 2020-05-07 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
PE20211655A1 (es) 2018-10-31 2021-08-24 Gilead Sciences Inc Compuestos de 6-azabencimidazol sustituidos como inhibidores de hpk1
TWI826690B (zh) 2019-05-23 2023-12-21 美商基利科學股份有限公司 經取代之烯吲哚酮化物及其用途
PH12022550605A1 (en) * 2019-09-13 2023-09-25 Nimbus Saturn Inc Hpk1 antagonists and uses thereof
JP7303948B2 (ja) * 2020-05-01 2023-07-05 ファイザー・インク Ｈｐｋ１阻害薬としてのアザラクタム化合物
CN112409268A (zh) * 2020-12-03 2021-02-26 西南交通大学 靶向Fam20C抑制剂的制备及其抗三阴性乳腺癌作用
CN117295737A (zh) * 2021-03-05 2023-12-26 林伯士萨顿公司 Hpk1拮抗剂和其用途
WO2022213062A1 (en) 2021-03-29 2022-10-06 Nimbus Saturn, Inc. Hpk1 antagonists and uses thereof
WO2022258044A1 (zh) * 2021-06-11 2022-12-15 杭州中美华东制药有限公司 吡咯并吡啶酮类化合物及其制备方法和用途
EP4373817B1 (en) 2021-07-20 2025-05-21 Astrazeneca AB Substituted pyrazine-2-carboxamides as hpk1 inhibitors for the treatment of cancer
US20250011331A1 (en) * 2021-08-03 2025-01-09 Nimbus Saturn, Inc. Hpk1 antagonists and uses thereof
WO2023023942A1 (en) * 2021-08-24 2023-03-02 Biofront Ltd (Cayman) Hpk1 inhibitors, compositions comprising hpk1 inhibitor, and methods of using the same
WO2023030478A1 (zh) * 2021-09-03 2023-03-09 浙江海正药业股份有限公司 吡啶并内酰胺类衍生物及其制备方法和用途
WO2023057883A1 (en) * 2021-10-05 2023-04-13 Pfizer Inc. Crystalline form of azalactam compound
CN114767676B (zh) 2022-04-22 2024-04-19 珠海宇繁生物科技有限责任公司 Hpk1激酶抑制剂在预防和/或治疗人的病原体感染中的应用
KR102855849B1 (ko) 2022-11-25 2025-09-08 충남대학교산학협력단 이미다조피리딘 유도체, 이를 유효성분으로 포함하는 약제학적 조성물 및 이를 이용하는 암의 치료 방법

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
US5243049A (en) * 1992-01-22 1993-09-07 Neurogen Corporation Certain pyrroloquinolinones: a new class of GABA brain receptor ligands
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO2000035298A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Chewing gum containing medicament active agents
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
WO2009014637A2 (en) * 2007-07-19 2009-01-29 Schering Corporation Heterocyclic amide compounds as protein kinase inhibitors
KR102537985B1 (ko) 2016-09-12 2023-05-30 인테그랄 헬스 인코퍼레이티드 Gpr120 조정제로서 유용한 단환형 화합물
JP7132937B2 (ja) 2017-03-15 2022-09-07 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Ｈｐｋ１の阻害剤としてのアザインドール
WO2019015559A1 (zh) 2017-07-18 2019-01-24 南京圣和药业股份有限公司 作为ask抑制剂的杂环化合物及其应用
EP3743063A4 (en) 2018-01-26 2021-10-20 Nurix Therapeutics, Inc. CBL-B INHIBITORS AND THEIR METHODS OF USE

Also Published As

Publication number Publication date
US11142525B2 (en) 2021-10-12
BR112021008991A2 (pt) 2021-08-10
JP7118267B2 (ja) 2022-08-15
DOP2021000088A (es) 2021-06-30
CR20210251A (es) 2021-07-14
HUE063367T2 (hu) 2024-01-28
ZA202103099B (en) 2023-11-29
ES2958948T3 (es) 2024-02-16
PL3880676T3 (pl) 2023-12-11
PE20211868A1 (es) 2021-09-21
IL283149A (en) 2021-06-30
UY38471A (es) 2020-06-30
MX2021005754A (es) 2021-08-11
EP3880676A1 (en) 2021-09-22
LT3880676T (lt) 2023-09-25
TW202031657A (zh) 2020-09-01
CL2021001190A1 (es) 2021-12-24
RS64655B1 (sr) 2023-10-31
EP3880676B1 (en) 2023-08-02
GEP20227434B (en) 2022-10-25
DK3880676T3 (da) 2023-09-04
PH12021551117A1 (en) 2021-11-22
SG11202104394XA (en) 2021-05-28
PT3880676T (pt) 2023-10-04
UA127426C2 (uk) 2023-08-16
US20200172539A1 (en) 2020-06-04
CO2021006114A2 (es) 2021-05-31
TWI718758B (zh) 2021-02-11
CN113316576A (zh) 2021-08-27
HRP20231089T1 (hr) 2023-12-22
SI3880676T1 (sl) 2023-10-30
CA3061392A1 (en) 2020-05-15
AU2019378184A1 (en) 2021-05-27
FI3880676T3 (fi) 2023-09-15
MD3880676T2 (ro) 2023-12-31
AU2019378184B2 (en) 2022-09-15
CY1126663T1 (el) 2026-02-25
ECSP21034668A (es) 2021-06-30
KR20210090675A (ko) 2021-07-20
WO2020100027A1 (en) 2020-05-22
GEAP202215630A (en) 2022-06-27
JP2022507231A (ja) 2022-01-18
CU20210035A7 (es) 2021-12-08

Similar Documents

Publication Publication Date Title
CL2021001190A1 (es) Compuestos de azalactam como inhibidores de hpk1
PY2005283A (es) Inhibidores de cdk2
ECSP20067394A (es) Inhibidores de cinasa dependientes de ciclina
CR20200484A (es) COMPUESTOS DE DIHIDROISOQUINOLINONA SUSTITUIDA (Divisional 2016-0574)
ECSP21091615A (es) Derivados de benzisoxazol sulfonamida
CO2022008091A2 (es) Inhibidores de kras g12c
NI201900013A (es) Inhibidor de piridopirimidinona cdk2/4/6
CO2019011762A2 (es) Compuestos que inhiben la proteína mcl-1
MX2022001158A (es) Inhibidores dobles de atm y adn-pk para uso en terapias antitumorales.
UY39303A (es) Inhibidores de mutación her2
PY2253236A (es) Inhibidores de mutacion de her2
CO2022015448A2 (es) Compuestos de azalactama como inhibidores de hpk1
MX2021012499A (es) Inhibidores mejorados del complejo de activación transcripcional notch y métodos para el uso de estos.
AR119557A1 (es) Compuestos de 7,8-dihidro-4h-pirazolo[4,3-c]azepina-6-ona
PY2153042A (es) Inhibidores de mutación her2
AR122805A1 (es) Inhibidores de mutación her2
DOP2016000326A (es) Compuestos de dihidroisoquinolinona sustituida